Pfizer, BioNTech coronavirus vaccine candidate gins up antibodies in early trial HHS: COVID-19 testing reaching capacity at some labs as states grapple with spikes 5 FDA-approved antivirals could target COVID-19: study Lawmakers press CDC for plan on distributing COVID-19 vaccine Fujifilm pairs with Dr. Reddy's, Global Response Aid to make COVID-19 drug Avigan AHA: Hospitals could lose $20B a month for rest of 2020 due to COVID-19 impact Healthcare roundup: Society of Actuaries tool allows payers to model COVID costs Biopharma roundup: Five approved antivirals could fight COVID, researchers say; FDA vaccine guidance vague on emergency use Even after FDA's coronavirus vaccine guidance, the emergency path remains a mystery: GlobalData More than two-thirds of trials hit by COVID-19 enrollment halts, with midstage tests the worst affected Featured Story | By Eric Sagonowsky With the eyes of the world turned on the global COVID-19 vaccine race, Pfizer and its partner BioNTech have posted early positive data from one of their four candidates. With the results and others yet to come, the partners are prepping for a late-stage trial that could begin as early as this month. read more |
| |
|---|
|
Top Stories By Robert King Some labs are starting to reach capacity for COVID-19 testing as several states reach record-level cases of the virus. read more By Arlene Weintraub Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, reported researchers from Columbia University and the University of Wisconsin-Madison. What's key is their ability to disrupt a protein called polymerase. read more By Robert King Senators pressed the Trump administration to put out a plan on how to distribute a vaccine and combat mistrust among the public to vaccines. read more By Angus Liu Meeting global demand for a potential COVID-19 treatment is more than any one company can handle on its own. For Fujifilm, it has signed on India’s Dr. Reddy’s Laboratories and Dubai-based Global Response Aid to manufacture and sell its flu drug Avigan for potential treatment of COVID-19. read more By Robert King Hospital financial losses are expected to continue through the rest of the year due to COVID-19, with an AHA analysis estimating losses of $120 billion from July through December. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Pfizer and BioNTech posted early data showing their mRNA vaccine candidate generated promising antibody levels in COVID patients. Plus, researchers from Columbia University and the University of Wisconsin-Madison identified five FDA-approved drugs that could halt the virus' spread. An analyst took issue with FDA's vaccine guidance. And more. read more By Eric Sagonowsky In reviewing potential COVID-19 vaccines, FDA commissioner Stephen Hahn has pledged to "not cut corners" or allow politics to affect decision-making. But while the agency has laid out clear efficacy requirements for a full approval, its emergency use authorization pathway isn't so clear, GlobalData says. read more By Ben Adams Nearly 200 companies have stopped or delayed their trials over the pandemic, and life science analytics firm GlobalData has dug into the data and found the main culprit has been suspended enrollment. read more | | [Webinar] Mastering the Virtual Clinical Trial Now available on demand! This Fierce webinar will bring together executives with expertise in R&D and technology implementation to explain the potential benefits of virtual clinical trials, as well as the ins and outs of designing and running them. It will include representatives from companies that have completed virtual clinical trials successfully and can provide advice on what did and did not work. Watch now. |
|
